These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32880915)

  • 1. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.
    Forde S; Matthews JD; Jahangiri L; Lee LC; Prokoph N; Malcolm TIM; Giger OT; Bell N; Blair H; O'Marcaigh A; Smith O; Kenner L; Bomken S; Burke GAA; Turner SD
    Br J Haematol; 2021 Jan; 192(2):354-365. PubMed ID: 32880915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
    Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
    Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
    J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations.
    Aukema SM; Theil L; Rohde M; Bauer B; Bradtke J; Burkhardt B; Bonn BR; Claviez A; Gattenlöhner S; Makarova O; Nagel I; Oschlies I; Pott C; Szczepanowski M; Traulsen A; Kluin PM; Klapper W; Siebert R; Murga Penas EM
    Br J Haematol; 2015 Sep; 170(6):814-25. PubMed ID: 26104998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
    Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
    Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
    Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
    Mrdenovic S; Zhang Y; Wang R; Yin L; Chu GC; Yin L; Lewis M; Heffer M; Zhau HE; Chung LWK
    Cancer; 2019 Jul; 125(13):2222-2232. PubMed ID: 30840322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
    Yoon J; Yun JW; Jung CW; Ju HY; Koo HH; Kim SH; Kim HJ
    Genes Chromosomes Cancer; 2020 Apr; 59(4):255-260. PubMed ID: 31705772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
    Jakobsen LH; Ellin F; Smeland KB; Wästerlid T; Christensen JH; Jørgensen JM; Josefsson PL; Øvlisen AK; Holte H; Blaker YN; Grauslund JH; Bjørn J; Molin D; Lagerlöf I; Smedby KE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song KW; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TC
    Br J Haematol; 2020 May; 189(4):661-671. PubMed ID: 32017050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue.
    Masqué-Soler N; Szczepanowski M; Kohler CW; Aukema SM; Nagel I; Richter J; Siebert R; Spang R; Burkhardt B; Klapper W
    Br J Haematol; 2015 Nov; 171(4):501-8. PubMed ID: 26218299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and treatment outcomes of children and adolescents with aggressive mature B-cell lymphoma: a single-center analysis.
    Jeon W; Koh YK; Kang S; Kim H; Koh KN; Im HJ
    Blood Res; 2022 Mar; 57(1):41-50. PubMed ID: 35256548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.
    Klingenberg M; Becker J; Eberth S; Kube D; Wilting J
    BMC Cancer; 2014 May; 14():339. PubMed ID: 24884418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
    Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.